Parkinson's disease: The case for novel treatment strategies

被引:3
|
作者
Stern, MB
Freese, A
机构
[1] UNIV PENN,SCH MED,DIV NEUROSURG,PHILADELPHIA,PA 19104
[2] BOCKUS RES INST,MOL NEUROSURG LAB,PHILADELPHIA,PA 19146
关键词
D O I
10.1006/exnr.1996.6378
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Over the past 30 years, significant strides have been made toward improving symptomatic therapy of patients with Parkinson's disease. However limitations persist, and the incremental improvement each new drug offers a patient yields only a minimal advantage therapeutically, Therefore, to alter meaningfully the natural course of this debilitating disorder, which becomes more prevalent each year in our society, significant novel therapeutic approaches must be tested. Genetic intervention in Parkinson's disease may offer an entirely different method for treating this disease in the future, based not only on symptomatic therapy, but also on neuroprotective and/or neuroregenerative therapy which would alter the natural history of relentless progression. (C) 1997 Academic Press.
引用
收藏
页码:2 / 3
页数:2
相关论文
共 50 条
  • [31] Novel pharmaceuticals in the treatment of psychosis in Parkinson's disease
    Broadstock, Martin
    Ballard, Clive
    Corbett, Anne
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2014, 7 (06) : 779 - 786
  • [32] Novel pharmacological targets for the treatment of Parkinson's disease
    Anthony H. V. Schapira
    Erwan Bezard
    Jonathan Brotchie
    Frédéric Calon
    Graham L. Collingridge
    Borris Ferger
    Bastian Hengerer
    Etienne Hirsch
    Peter Jenner
    Nicolas Le Novère
    José A. Obeso
    Michael A. Schwarzschild
    Umberto Spampinato
    Giora Davidai
    Nature Reviews Drug Discovery, 2006, 5 : 845 - 854
  • [33] Glunomab: a novel therapeutics for the treatment of Parkinson's Disease
    Torrente, D.
    Su, E.
    Schielke, G. P.
    Warnock, M.
    Stevenson, T.
    Mann, K.
    Lesept, F.
    Deletage, N.
    Blanc, M.
    Vivien, D.
    Lawrence, D.
    MOVEMENT DISORDERS, 2023, 38 : S595 - S595
  • [34] A novel treatment for Parkinson's disease using an immunomodulator
    Sredni, B
    Yadid, G
    Albeck, M
    Shalit, F
    Gefen, R
    JOURNAL OF NEUROCHEMISTRY, 2003, 85 : 40 - 40
  • [35] Novel pharmacological targets for the treatment of Parkinson's disease
    Schapira, Anthony H. V.
    Bezard, Erwan
    Brotchie, Jonathan
    Calon, Frederic
    Collingridge, Graham L.
    Ferger, Borris
    Hengerer, Bastian
    Hirsch, Etienne
    Jenner, Peter
    Le Novere, Nicolas
    Obeso, Jose A.
    Schwarzschild, Michael A.
    Spampinato, Umberto
    Davidai, Giora
    NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (10) : 845 - 854
  • [36] Implications of Successful Symptomatic Treatment in Parkinson's Disease for Therapeutic Strategies of Alzheimer's Disease
    Zhao, Lei
    Cheng, Xiaoqin
    Zhong, Chunjiu
    ACS CHEMICAL NEUROSCIENCE, 2019, 10 (02): : 922 - 930
  • [37] Antidiabetic agents as a novel treatment for Alzheimer's and Parkinson's disease
    Nowell, Joseph
    Blunt, Eleanor
    Gupta, Dhruv
    Edison, Paul
    AGEING RESEARCH REVIEWS, 2023, 89
  • [38] Dopamine agonist-based strategies in the treatment of Parkinson’s disease
    Angelo Antonini
    Paolo Barone
    Neurological Sciences, 2008, 29 : 371 - 374
  • [39] Device-Aided Treatment Strategies in Advanced Parkinson's Disease
    Timpka, Jonathan
    Nitu, Bianca
    Datieva, Veronika
    Odin, Per
    Antonini, Angelo
    PARKINSON'S DISEASE, 2017, 132 : 453 - 474
  • [40] Stem-cell-based strategies for the treatment of Parkinson's disease
    Parish, Clare L.
    Arenas, Ernest
    NEURODEGENERATIVE DISEASES, 2007, 4 (04) : 339 - 347